ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on December 12, 2025, regarding events occurring on December 9, 2025, at the Company's 2025 Annual Meeting of Stockholders. The filing details the results of shareholder votes and corporate governance amendments.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and shareholder voting results.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation, increasing authorized common stock from 20,000,000 shares to 1,000,000,000 shares. This amendment was filed with the Delaware Secretary of State on December 10, 2025.
- Compensation Plan Amendment: Stockholders approved the Second Amendment to the 2016 Omnibus Incentive Plan.
- Director Elections: Four directors (Louis J. Basenese, Anthony DiGiandomenico, Michael Harsh, and Alexander Tokman) were elected to serve until the next annual meeting.
- Auditor Ratification: RBSM LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Failed Proposal: Stockholders did not approve a proposal to amend the Certificate of Incorporation to provide for officer exculpation as permitted by Delaware law.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific risk factors. The primary risk highlighted by the voting results is the shareholder rejection of the officer exculpation proposal, which may impact the Company's ability to limit liability for its officers under Delaware law.
Investor Verification Checklist
- Verify the full text of the Second Amendment to the 2016 Omnibus Incentive Plan in Appendix B of the October 28, 2025 Proxy Statement.
- Review the Certificate of Amendment (Exhibit 3.1) to understand the specific terms of the 1,000,000,000 share authorization increase.
- Assess the implications of the failed officer exculpation proposal on the Company's governance structure and potential liability exposure.
- Confirm the total number of shares outstanding versus the new authorized limit to evaluate dilution potential.